Browsing by Author "Açıkgöz, Özgür"
Now showing items 1-20 of 22
-
The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: A multicenter study
Akdeniz, Nadiye; Kaplan, Muhammet Ali; Uncu, Doğan; İnanç, Mevlüde; Kaya, Serap; Dane, Faysal; Küçüköner, Mehmet; Demirci, Ayşe; Bilici, Mehmet; Gök Durnalı, Ayşe; Koral, Lokman; Şendur, Mehmet Ali Nahit; Erol, Cihan; Türkmen, Esma; Ölmez, Ömer Fatih; Açıkgöz, Özgür; Laçin, Şahin; Şahinli, Hayriye; Urakçı, Zuhat; Işıkdoğan, Abdurrahman (Springer, 2021)Purpose We aim to compare the efficiency and toxicity of three different 5-fluorouracil (5-FU) administration types in 5-FU, leucovorin, and oxaliplatin (FOLFOX) combination treatment for adjuvant therapy in colorectal ... -
Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer
Göktaş Aydın, Sabin; Bilici, Ahmet; Çalış, Elif; Kutlu, Yasin; Hamdard, Jamshid; Muğlu, Harun; Ölmez, Ömer Fatih; Karcı, Ebru; Açıkgöz, Özgür (Elsevier B.V., 2023)Background: Non-small cell lung cancer (NSCLC) often exhibits elevated Secreted Protein Acidic and Cysteine-Rich (SPARC) expression. In this study, we investigated the impact of SPARC expression on clinicopathologic features, ... -
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
Kutlu, Yasin; Göktaş Aydın, Sabin; Bilici, Ahmet; Öven, Bala Başak; Ölmez, Ömer Fatih; Açıkgöz, Özgür; Hamdard, Jamshid (NLM (Medline), 2023)Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy ... -
Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer
Açıkgöz, Özgür; Çakan, Burçin; Demir, Tarık; Bilici, Ahmet; Öven, Bala Başak; Hamdard, Jamshid; Olmuşçelik, Oktay; Ölmez, Ömer Fatih; Şeker, Mesut; Yıldız, Özcan (Lippincott Williams & Wilkins, 2021)The aim of this study was to investigate the predictive and prognostic value of PLR, and the relationship between PLR and tumor localization. A total of 229 patients with de-novo metastatic CRC were retrospectively analyzed. ... -
Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Bilici, Ahmet; Çakan, Banu; Demir, Tarık; Öven, Bala Başak; Açıkgöz, Özgür; Hamdard, Jamshid; Ölmez, Ömer Fatih; Ölmüşçelik, Olcay; Şeker, Mesut; Yıldız, Özcan (Oxford University Press, 2019)Background The prognostic importance of platelet-to-lymphocyte ratio(PLR)has been also investigated in some cancer types including colorectal cancer (CRC).Several studies have found that PLR is associated with poor prognosis ... -
Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
Göktaş Aydın, Sabin; Kutlu, Yasin; Muğlu, Harun; Aydın, Ahmet; Açıkgöz, Özgür; Hamdard, Jamshid; Karcı, Ebru; Bilici, Ahmet; Ölmez, Ömer Fatih; Yıldız, Özcan (Springer, 2024)Background: Prostate cancer is a prevalent cancer in men worldwide, and castration-resistant prostate cancer (CRPC) is characterized by disease progression despite androgen deprivation therapy. While clinical and prognostic ... -
Pretreatment platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as a predictor of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: Single center experience from Turkey
Açıkgöz, Özgür; Yıldız, Anıl; Bilici, Ahmet; Ölmez, Ömer Fatih; Basım, Pelin; Çakır, Aslı (Lippincott Williams and Wilkins, 2022)The aim of this study was to investigate the predictive value of PLR and NLR as an indicator of pathological complete response (pCR) in patients with breast cancer after NACT. One hundred thirty-nine patients with early ... -
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes
Yıldız, Anıl; Bilici, Ahmet; Açıkgöz, Özgür; Hamdard, Jamshid; Basım, Pelin; Çakır, Tansel; Çakır, Aslı; Ölmez, Ömer Fatih; Gezen, Cem; Yıldız, Özcan (Taylor and Francis Ltd., 2024)The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 to ... -
The prognostic role of mismatch repair status and CDX-2 expression with inflammatory markers and pathological risk factors in stage ıı and ııı colon cancer: Multicenter real-life data
Aydın, Sabin Göktaş; Ölmez, Ömer Fatih; Selvi, Oğuzhan; Geredeli, Çağlayan; Özden, Ferhat; Bilici, Ahmet; Açıkgöz, Özgür; Karcı, Ebru; Kutlu, Yasin; Hamdard, Jamshid; Aydın, Ahmet (2024)Objective: Colorectal cancer is common worldwide, and adjuvant treatment’s benefit is still controversial. We designed this study to determine the role of MSI and CDX-2 status determined by immunohistochemistry (IHC) ... -
Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
Kutlu, Yasin; Çekin, Ruhper; Göktaş Aydın, Sabin; Shbair, Abdallah T. M.; Bilici, Ahmet; Arıcı, Serdar; Öven, Bala Başak; Açıkgöz, Özgür; Özcan, Erkan; Ölmez, Ömer Fatih; Çakır, Aslı; Şeker, Mesut (2024)Loss of human epidermal growth factor receptor 2 (HER2) expression can be seen in almost 25–30 % patients after HER2 receptor directed neoadjuvant treatment. These patients have unclear clinical outcomes in previous studies. ... -
Prognostic significance of metastatic lymph node ratio in patients with pN3 gastric cancer who underwent curative gastrectom
Bilici, Ahmet; Biricik, Fatih Selçuk; Şeker, Mesut; Öven, Başak Bala; Ölmez, Ömer Fatih; Yıldız, Özcan; Ölmüşçelik, Oktay; Hamdard, Jamshid; Açıkgöz, Özgür; Çakır, Aslı; Kapran, Yersu; Balık, Emre; Öncel, Mustafa (Karger, 2019)Background: Lymph node involvement is an important prognostic factor in patients with gastric cancer. The aim of this study was to determine the prognostic significance of metastatic lymph node ratio (MLNR) and compare it ... -
Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey
Çakan, Burçin; Açıkgöz, Özgür; Bilici, Ahmet; Demir, Tarık; Öven, Bala Başak; Hamdard, Jamshid; Olmuşçelik, Oktay; Ölmez, Ömer Fatih; Şeker, Mesut; Yıldız, Özcan (Zerbinis Publications, 2021)Purpose: The purpose of this study was to investigate the prognostic value,and the effect of primary tumor location on targeted therapy selection in patients with metastatic colorectal cancer (mCRC). Methods: A total of ... -
Rare side effect caused by atezolizumab, an immune checkpoint inhibitor: Cold agglutinin disease
Açıkgöz, Özgür; Bayramgil, Ayberk; Çavuşoğlu, Güneş; Sadri, Sevil (SAGE Publications Ltd, 2021)Introduction Immune checkpoint inhibitors are drugs that are included in the guidelines of hematological and solid cancer treatments, give highly effective results and increase T cell functionality. However, these drugs ... -
Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study
Bilici, Ahmet; Uysal, Mükremin; Menekşe, Serkan; Akın, Semih; Yıldız, Fatih; Turan, Merve; Sezgin Göksu, Sema; Beypınar, İsmail; Sakalar, Teoman; Değirmenci, Mustafa; Erdem, Dilek; Başaran, Gül; Ölmez, Ömer Fatih; Avcı, Nilüfer; Tural, Deniz; Sakin, Abdullah; Türker, Sema; Demir, Atakan; Temiz, Süleyman; Kaplan, Muhammed Ali; Doğan, Mutlu; Tanrıverdi, Özgür; Bilgetekin, İrem; Yeşil Çınkır, Havva; Açıkgöz, Özgür; Paydaş, Semra; Uslu, Rüçhan; Turhal, Serdar (Taylor & Francis Inc, 2022)Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) ... -
Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
Aydın, S. G.; Kutlu, Yasin; Açıkgöz, Özgür; Bilici, A.; Hamdard, Jamshid; Ölmez, Ömer Fatih; Yıldız, Özcan (Elsevier Science Inc., 2021)Introduction: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer and in the absence of driver mutation preferred treatment is incorporation of immunotherapy.But for patients treated with chemotherapy ... -
Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
Göktaş Aydın, Sabin; Açıkgöz, Özgür; Kutlu, Yasin; Bilici, Ahmet; Hamdard, Jamshid; Ölmez, Ömer Fatih; Yıldız, Özcan (Ankara Society of Hematology and Oncology, 2021)Background: Immunotherapy agents such as atezolizumab and nivolumab are appropriate option for non-small cell lung cancer (NSCLC) accounts in the absence of driver mutation, regardless of PDL-1 expression in second and ... -
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Açıkgöz, Özgür; Sezer, Ahmet; Gürbüz, Mustafa; Ak, Naziye; Yücel, Şebnem; Ayhan, Murat; Erol, Cihan; Demirkıran, Aykut; Mandel, Nil Molinas; Shbair, Abdallah; Gökmen, İvo; Başoğlu, Tuğba; Paydaş, Semra; Demiray, Atike Gökçen; İriağaç, Yakup; Şakalar, Teoman; Zeynelgil, Esra; Tatlı, Ali Murat; Bahçeci, Aykut; Güven, Deniz Can; Caner, Burcu; Can, Alper; Gülmez, Ahmet; Karakaş, Yusuf; Yalçın, Bülent; Demirkazık, Ahmet; Bilici, Ahmet; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Springer, 2022)Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ... -
Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer
Erol, Vedat Buğra; Göktaş Aydın, Sabin; Bilici, Ahmet; Çakır, Aslı; Açıkgöz, Özgür; Ölmez, Ömer Fatih; Basım, Pelin (Taylor and Francis Ltd., 2023)To evaluate the tumour-infiltrating lymphocyte (TIL) rates in breast tissue before and after neoadjuvant chemotherapy (NAC) and their impact on survival, eighty-four patients with locally advanced breast cancer (LABC) were ... -
The role of 18F-FDG PET/CT in predicting the neoadjuvant treatment response in patients with locally advanced breast cancer
Göktaş Aydın, Sabin; Bilici, Ahmet; Ölmez, Ömer Fatih; Öven, Bala Başak; Açıkgöz, Özgür; Çakır, Tansel; Basım, Pelin; Çakır, Aslı; Kutlu, Yasin; Hamdard, Jamshid (Karger, 2022)Purpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy ... -
Survival effect of palliative radiotherapy in patients with metastatic castration-resistant prostate cancer developing oligo-progression under antiandrogen treatment
Göktaş Aydın, Sabin; Kutlu, Yasin; Muğlu, Harun; Açıkgöz, Özgür; Aydın, Ahmet; Bilici, Ahmet; Ölmez, Ömer Fatih; Ünal, Dilek; Karcı, Ebru; Yıldız, Özcan (Istanbul University, 2023)Objective: Androgen pathway inhibitors have a significant impact on the treatment of prostate cancer. The treatment approach is controversial in patients who develop oligo-pro-gression under anti-androgen therapy. This ...